



DAE
\$
Seq Listing

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	ATTY'S DKT: GILAD2B
)	
GILAD et al.)	January 6, 2004
)	
Appln. No.: 09/833,031)	
)	Washington, D.C.
Filed: April 11, 2001)	
)	Conf. No. 8372
For: METHOD FOR ENRICHMENT...)	
)	Attn: PETITIONS

PETITION TO VACATE HOLDING OF ABANDONMENT¹

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir:

Applicants are in receipt of the Notice of Abandonment, mailed December 12, 2003, which **erroneously** states that the application is abandoned because of applicants failure to file a reply within the time period established by the Notice to File Missing Parts, dated October 22, 2001.

It is respectfully requested that such Notice of Abandonment be vacated as being erroneous and that the present application be reinstated.

THE FACTS

The Notice to File Missing Parts dated October 22, 2001, was actually a Withdrawal of Previously Sent Notice and a

¹ If a fee must be charged, please charge same to Deposit Account No. 02-4035, and then refund said fee as the holding of abandonment is erroneous and is entirely the fault of the PTO.

RECEIVED

JAN 08 2004

OFFICE OF PETITIONS

Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. The notice entitled "Withdrawal of Previously Sent Notice" withdrew the Notice previously mailed on October 2, 2001, which was a "Notice of Incomplete Reply". Said "Notice of Incomplete Reply" indicated that the content of the computer readable form of the sequence listing previously submitted did not comply. The deadline for responding to the "Notice of Incomplete Reply" continued to run from the original Notice to File Missing Parts dated June 7, 2001. Thus, the next deadline for responding to the "Notice of Incomplete Reply" was October 7, 2001.

Applicants timely responded. Thus, in response to the "Notice of Incomplete Reply", a substitute sequence listing meeting all the requirements as set forth in the Notice of Incomplete Reply was filed on October 5, 2001, along with a petition for a two months extension of time and the required petition fee of \$200.00.

When the "Withdrawal of Previously Sent Notice and the Notice to Comply..." dated October 22, 2001, were received, the undersigned reviewed the requirements and determined that it was just a reiteration of the requirements previously set forth in the "Notice of Incomplete Reply". The only difference between the two notices was the time period for

response. As a fully responsive reply had already been filed on October 5, 2001, nothing further needed to be filed, as the proper paper sequence had already been submitted.

As evidence that such proper paper sequence was timely and properly filed on October 5, 2001, attached hereto is a xerographic copy of the return postcard date-stamped by the PTO Mail Room as having been timely received by the PTO on October 5, 2001.

As it appears that the Response filed on October 5, 2001, has been lost by and in the PTO, attached hereto is a duplicate copy of the Response [entitled "Response to Notice of Incomplete Reply (Nonprovisonal)] dated October 5, 2001, freshly re-signed and related papers. **No further fees are required at this time.**


REMARKS

In view of the above evidence, it is clear that a Reply was timely and properly filed within the time period established by the Notice of Incomplete Reply, dated October 2, 2001, and the Notice to Comply dated October 22, 2001, and that the Notice of Abandonment has been issued in error. Indeed, the postcard by itself should be sufficient, as MPEP Section 503 states:

A postcard receipt which itemizes and properly identifies the papers which are being filed serves as prima facie evidence of receipt of the PTO of all items listed there on the date stamped thereon by the PTO.

It is accordingly requested that the Notice of Abandonment be vacated and the present application be reinstated.

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant


By 
Allen C. Yun
Registration No. 37,971

ACY:edg

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

G:\BN\Q\QBI\Gilad2B\PTO\patent erroneous abandonment.doc



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Box Sequence
Shlomit GILAD et al.)	Examiner:
Appln. No.: 09/833,031)	Washington, D.C.
Filed: April 11, 2001)	October 5, 2001
For: METHOD FOR ENRICHMENT OF NATURAL ANTISENSE...)	Atty. Docket: GILAD=2B

RESPONSE TO NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice of Incomplete Reply (Nonprovisional) dated October 2, 2001, a petition for a two month extension of time being attached hereto, and prior to the examination of the above-described application, please amend the present application as follows:

IN THE SEQUENCE LISTING

Please substitute the paper copy Sequence Listing attached hereto for the Sequence Listing last filed on July 31, 2001.

RECEIVED

JAN 08 2004

OFFICE OF PETITIONS

REMARKS

Applicants have added into the present specification a substitute paper copy Sequence Listing section according to 37 C.F.R. §1.821(c). Furthermore, attached hereto is a 3 1/2" disk containing the "Sequence Listing" in computer readable form in accordance with 37 C.F.R. §1.821(e).

The following statement is provided to meet the requirements of 37 C.F.R. §1.825(a) and 1.825(b).

I hereby state, in accordance with 37 C.F.R. §1.825(a), that the amendments included in the substitute sheets of the sequence listing are believed to be supported in the application as filed and that the substitute sheets of the sequence listing are not believed to include new matter.

I hereby further state, in accordance with 37 C.F.R. §1.825(b), that the attached copy of the computer readable form is the same as the attached substitute paper copy of the sequence listing.

Under U.S. rules, each sequence must be classified in <213> as an "Artificial Sequence", a sequence of "Unknown" origin, or a sequence originating in a particular organism, identified by its scientific name.

Neither the rules nor the MPEP clarify the nature of the relationship which must exist between a listed sequence and an organism for that organism to be identified as the origin of the sequence under <213>.

Hence, counsel may choose to identify a listed sequence as associated with a particular organism even though

that sequence does not occur in nature by itself in that organism (it may be, e.g., an epitopic fragment of a naturally occurring protein, or a cDNA of a naturally occurring mRNA, or even a substitution mutant of a naturally occurring sequence). Hence, the identification of an organism in <213> should not be construed as an admission that the sequence *per se* occurs in nature in said organism.

Similarly, designation of a sequence as "artificial" should not be construed as a representation that the sequence has no association with any organism. For example, a primer or probe may be designated as "artificial" even though it is necessarily complementary to some target sequence, which may occur in nature. Or an "artificial" sequence may be a substitution mutant of a natural sequence, or a chimera of two or more natural sequences, or a cDNA (i.e., intron-free sequence) corresponding to an intron-containing gene, or otherwise a fragment of a natural sequence.

The Examiner should be able to judge the relationship of the enumerated sequences to natural sequences by giving full consideration to the specification, the art cited therein, any further art cited in an IDS, and the results of his or her sequence search against a database containing known natural sequences.

Applicants submit that the present application contains patentable subject matter and therefore urge the examiner to pass the case to issuance.


In re Appln. No. 09/833,031

If the examiner has any questions or comments concerning the above described application, the examiner is urged to contact the undersigned at the phone number below.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By



Allen C. Yun
Registration No. 37,971

ACY:pr
624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528

F:\Q\QBI\G11ad2B\PTO\RESPONSE TO NOTICE TO COMPLY.wpd



SEQUENCE LISTING

<110> GILAD, Shlomit
EINAT, Paz
GROSMAN, Avital

<120> METHOD FOR ENRICHMENT OF NATURAL ANTISENSE MESSENGER RNA

<130> GILAD=2B

<140> 09/833,031

<141> 2001-04-11

<150> 09/680,420

<151> 2000-10-06

<160> 29

<170> PatentIn version 3.1

<210> 1

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide primer

<220>

<221> misc_feature

<222> (40)..(40)

<223> n is a, c, g or t.

<400> 1

ttctagaatt cagcggccgc tttttttttt tttttttvn

40

<210> 2

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide primer

<400> 2

gatgggagtt gtgtgttttag tc

22

<210> 3

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide primer

<400> 3

ggagagagaa gtgcagagtt cg

22

<210> 4

<211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide primer

<400> 4
 ttagtacaaa cttagggctc t

21

<210> 5
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide primer

<400> 5
 tcatggcaac tccagagcag

20

<210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide primer

<400> 6
 accacagtcc atgccatcac

20

<210> 7
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide primer

<400> 7
 tccaccaccc tgttgctgta

20

<210> 8
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide primer

<400> 8
 ggagttagtc cttgaccact ag

22

<210> 9
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Synthetic oligonucleotide primer

<400> 9

gcacttacac agttagtcat gg

22

<210> 10

<211> 188

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Amplified Sequence

<400> 10

gggcgggccg cttttttttt tttttttttg gagttagtcc ttgaccacta gtttgatgcc 60

atctccattt tgggtgacct gtttcaccag caggcctgtt actctccatg actaactgtg 120

taagtgttta aaatggaata aattgctttt ctacataacc ccaaaaaaaaa aaaaaaaaaa 180

gcggccgc 188

<210> 11

<211> 169

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Amplified Human

<400> 11

ttttttttt ttttttttgg agttagtcc tggaccactag tttgatgcc tctccatttt 60

gggtgacctg tttcaccagc aggcctgtta ctctccatga ctaactgtgt aagtgttaa 120

aatggaataa attgcttttc tacataaccc caaaaaaaaa aaaaaaaaaa 169

<210> 12

<211> 550

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Amplified Human

<220>

<221> misc_feature

<222> (115)..(115)

<223> n is unknown.

<220>

<221> misc_feature

<222> (189)..(189)

<223> n is unknown.

<220>

<221> misc_feature
 <222> (320)..(320)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (331)..(331)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (341)..(341)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (369)..(369)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (377)..(377)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (446)..(446)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (472)..(472)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (497)..(497)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (538)..(538)
 <223> n is unknown.

<400> 12
 ttttcattgt cataattttt tattatgtat caaattgtct tcaatataag ttacaacttg 60
 attaaagttg atagacattt gtatctattt aaagacaaaa aaattctttt atgtncaata 120
 tcttgtctag agtctagcaa atatagtacc tttcattgca ggattttctgc ttaatataac 180
 aagcaaaaanc aaacaactga aaaaatataa accaaagcaa accaaacccc ccgctcaact 240
 acaaagtga atattgaatg aagcattaaa agacaaacat aaagtaactt cagcttttat 300

ctagcaatgc agaatgaatn ctaaaattag nggcaaaaaa ncaaacaaca aacaacaaac 360
 aaaacaaanc aaacaancaa aaaatcccac caatcttcat gggtaaactt tcttgctcag 420
 ggatgtaagc tgactctaga ccattngcgg ttcttgcgga tagcacagcc angatcatct 480
 gaagatcatg ccaaantntca tgaccacggc aatgccgatg cccctgcgcc gatgatgngg 540
 aattttattgg 550

<210> 13
 <211> 491
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<400> 13
 tttttttttt tttttttctt gctgcagcaa cgcgagtggg agcaccagga tctcgggctc 60
 ggaacgagac tgcacggatt gttttaagaa aatggcagac aaaccagaca tgggggaaat 120
 cgccagcttc gataaggcca agctgaagaa aacggagacg caggagaaga acaccctgcc 180
 gaccaaagag accattgagc aggagaagcg gagtgaattt tcttaagatc ctggaggatt 240
 tcttaccccc atcctcttcg agaccccagt cgtgatgtgg aggaagagcc acctgcaaga 300
 tggacacgag ccacaagctg cactgtgaac ctgggcactc cgtgccgatg ccaccggcct 360
 gtgggtctct gaagggaccc ccccccaatc ggactgccaa attctccggt ttgccccggg 420
 atattataga aaattatttg tatgaataat gaaaataaaa cacacctcgt ggcaaaaaaa 480
 aaaaaaaaaa a 491

<210> 14
 <211> 206
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<400> 14
 tttttttttt ttttttttgg gagtggtagg atgaaacaat ttggagaaga tagaagtttg 60
 aagtggaaaa ctggaagaca gaagtacggg aaggcgaaga aaagaataga gaagataggg 120
 aaattagaag ataaaaacat acttttagaa gaaaaaagat aaattttaaac ctgaaaagta 180
 ggaagcagaa aaaaaaaaaa aaaaaa 206

<210> 15
 <211> 206
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<220>
 <221> misc_feature
 <222> (55)..(55)
 <223> n is unknown.

<400> 15
 ttttctgtgg ggccatcact ttattaaggg gtcacttaga aggtggggccc cctgncaaac 60
 cgcggggactg tgatcgggct ccagctactt caccaccccg ggccagcctg ctccaggggt 120
 cccttctctgc tgagagcagg cgagaggcag tcaggctcat gaagcagcca ccggggtttgg 180
 ctcaactggaa ggaatcacac tggaaa 206

<210> 16
 <211> 178
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<400> 16
 tttttttttt ttttttttct gtgtccactg gagagcttga gtcacactc aaagatcaga 60
 ggacctacag agagggctct ttggtttgag gaccatggct tacctttcct gcctttgacc 120
 catcacaccc catttctctc tctttccctc tccccgctgc caaaaaaaaa aaaaaaaa 178

<210> 17
 <211> 127
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<220>
 <221> misc_feature
 <222> (89)..(89)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (112)..(112)
 <223> n is unknown.

<400> 17
 gaattcgatg cgtattctgt ggcccgccat ctgcgcaggg tggtggtatt ctgccattta 60
 cacacgtcgt tctaattaaa aagcgaatna tactccaaaa aaaaaaaaaa angcgggcgt 120
 tgaattc 127

<210> 18
 <211> 115
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<400> 18
 gaattcagcg gccgcttttt tttttttttt tcttcgaagt gtttacccca gtgtttgaaa 60
 gggattccag atggtcaaata aaaaaaaatg ttcttaaact tggatgatg aactc 115

<210> 19
 <211> 204
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<220>
 <221> misc_feature
 <222> (28)..(28)
 <223> n is unknown.

<400> 19
 gaattcaggg ccgttctggt tctctctntc tccccgccct ccctcaccac cagtgaacc 60
 ttcacgcagt tccacaaacc tggatttttt atgtacaacc ctgaccgtg ccgtttgcta 120
 tattcctttt tctatgaaat aatgtgaatg ataataaaac agctttgact tgaaaaaaaa 180
 aaaaaaaaaag cggccgctga attc 204

<210> 20
 <211> 109
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<400> 20
 gaattccctc cccctccttg tgccttcttt gtatataggc ttctcacggc gaccaataaa 60
 cagctcccag tttgtatgca aaaaaaaaaa aaaagcggcc gctgaattc 109

<210> 21
 <211> 191
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<400> 21
 gaattcagcg gccgcttttt tttttttttt ttgggagaag tgtataaatt attatgttga 60

caagcagaga aagaaaagtt aaataccaga taagcttttg atttttgtat tgtttgcac 120
 cccttgccct caataaataa agttcttttt tagttccaaa aaaaaaaaaa aaaaaagcgg 180
 ccgctgaatt c 191

<210> 22
 <211> 106
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<400> 22
 gaattcagcg gaaaaccttg agttctggat tgctgtgag gattacaaga agatcaagtc 60
 ccctgccaaag atggctgaga aggcaaagca aatttatgaa gaattc 106

<210> 23
 <211> 63
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<400> 23
 gaattcaatg ggtaaataaa tgctgctttg gggaaaaaaaa aaaaaaaagc ggcgcgtgaa 60
 ttc 63

<210> 24
 <211> 586
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<220>
 <221> misc_feature
 <222> (527)..(527)
 <223> n is unknown.

<400> 24
 tttttttttt tttttttggc ctgggaatga gaaaataact ttatttcatt gtggggagcg 60
 ggccgatgtc cagcctcaga acttctggaa ctgcttcttg gtgccggcag ccttggtgac 120
 cttgagcacg ttgaagcgca ctgtcttgct cagaggccgg cactcgccca ctgtgacgat 180
 gtcaccgatc tggacgtccc tgaagcaggg ggacaggtgt acagacatgt tcttggtggcg 240
 cttctcgaag cggttgtact tgcggatgta gtgcagatag tctcggcgga tgacaatggt 300
 cctctgcac ttcattcttg tcaccacgcc agagaggatc cgccctcgaa tggacacatt 360
 accaagtga ggggcatttc ttgtcaatgt aggtgcctc aatagcctcc ttgggtgtct 420

tgaagcccag accgatgttc ttgtagtacc gcgggagctt ctccttgcca gtttctccca 480
gcaggaccct cttcttgttt tgaaagatgg tcggctgctt ttggtangca cgctcagtct 540
gaatgtccgc catcttcccg ggcgcctgaa aaaaaaaaaa aaaaaa 586

<210> 25
<211> 363
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Amplified Human

<400> 25
tttttttttt ttttttttcc ggcggtgacg acctacgcac acgagaacat gcctctcgca 60
aaggatctcc ttcattccctc tccagaagag gagaagagga aacacaagaa gaaacgcctg 120
gtgcagagcc ccaattccta cttcatggat gtgaaatgcc caggatgcta taaaatcacc 180
acggtcttta gccatgcaca aacggtagtt ttgtgtgttg gctgctccac tgctctctgc 240
cagcctacag gaggaaaagc aaggcttaca gaaggatggt ccttcaggag gaagcagcac 300
taaaagcact ctgagtcaag atgagtggga aaccatctca ataaacacat tttggataaa 360
ccg 363

<210> 26
<211> 563
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Amplified Human

<400> 26
tttttttttt tttttttctt cagcgaggcg gccgagctgg ttggtggcgg cggctcgtgcg 60
gacgcaaaca tgcagatctt tgtgaagacc ctactggca aaaccatcac ccttgaggtc 120
gagcccagtg acaccattga gaatgtcaaa gccaaaattc aagacaagga gggatatcca 180
cctgaccagc agcgtctgat atttgccggc aaacagctgg aggatggccg cactctctca 240
gactacaaca tccagaaaga gtccaccctg cacctggtgt tgcgcctgcg aggtggcatt 300
attgagcctt ctctccgcca gcttgcccag aaatacaact gcgacaagat gatctgccgc 360
aagtgctatg ctgccttca cctcgtgct gtcaactgcc gcaagaagaa gtgtggtcac 420
accaacaacc tgcgtcccaa gaagaagtc aaataaggtg gttctttcct tgaagggcag 480
cctcctgcc aggccccgtg gcctggagc ctcaataaag tgctcccttc attgactgga 540
gcagcaaaaa aaaaaaaaaa aaa 563

<210> 27

<211> 662
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<220>
 <221> misc_feature
 <222> (316)..(316)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (584)..(584)
 <223> n is unknown.

<220>
 <221> misc_feature
 <222> (633)..(633)
 <223> n is unknown.

<400> 27
 tttttttttt ttttttttgg gactttcagc ccctttaatt aggtgctctg agaagaggtc 60
 agaatggcag gcaggggggtg gggaaggcgg tgcttcttga gccccactta gcaactggtc 120
 actcatcctc tggcagctgg atcttgctgg ggtcgaagca gttggattcc atgatgggaa 180
 ggccattggc ctctcggtat ttcacaagcc tctcagcttc gggcggggac cactctttca 240
 tcccatccca cgctcttggga caccctgtgc acctgtagtc aggcagatag gccacaaagg 300
 tgctgccaag gaccangatg atggagacgc caaagaagaa gacaagtgcg atgttccaaa 360
 cgtccaaaaa cggggggccct gtcataacea atgggggaatc cggggtcctc ccatacaagt 420
 tttcgtcctc gggttctggg tctctttgcc acggtgtggt cggttctggg ggccgctttc 480
 ccgccacagc ggacggggcg accacaatcc tggagaaact agattcccaa cgggacgccg 540
 gcggggccggg aaccctcgcg tcgccgtgc cgccaaaaga ccngaacgc tcaaccaaac 600
 agccaaccgc aagacaaatg gtgctgaagg tcncaggggc ggaaagaaaa aaaaaaaaaa 660
 aa 662

<210> 28
 <211> 504
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Amplified Human

<400> 28
 tttttttttt ttttttttgg cttgactcag gatttaaaaa ctggaacggt gaaggtgaca 60
 gcagtgcggtt ggagcgagca tccccaaag ttcacaatgt ggccgaggac tttgattgca 120

```

cattgttggtt tttttaatag tcattccaaa tatgagatgc gttgttacag gaagtcctt 180
gccatcctaa aagccacccc acttctctct aaggagaatg gccagtcct ctccaagtc 240
cacacagggg aggtgatagc attgctttcg tgtaaattat gtaatgcaa atttttttaa 300
tcttcgcctt aatacttttt tttttgttt tttttgaat gatgagcctt cgtgcccccc 360
cttccccctt ttttgcccc caacttgaga tgtatgaagg cttttggtct ccctgggagt 420
gggtggaggc agccagggt tacctgtaca ctgacttgag accagtgaa taaaagtga 480
cacctgaaaa aaaaaaaaaa aaaa 504

```

```

<210> 29
<211> 66
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Synthetic

```

```

<400> 29
tctagtcgac ggccagtga ttgtaatacg actcactata gggcgttttt ttttttttt 60
tttttt 66

```



APPLICANT(S):

GILAD et al.

APPLICATION NO:

09/833,031

DOCKET NO.:

GILAD-2B

CONF. NO:

* THE PATENT AND TRADEMARK OFFICE STAMP
HEREON ACKNOWLEDGES RECEIPT OF THE
FOLLOWING PAPERS:

☒ FEES \$ 200.00

☒ PTO FORM 2038

☐ (CH. # _____)

☒ EXTENSION OF TIME (2 MONTHS)

☐ TRANSMITTAL LETTER

☐ MISSING PARTS RESPONSE WITH DECL

☐ AMENDMENT

☐ PRELIMINARY

☐ SUPPLEMENTAL

☐ REPLY TO OFFICE ACTION

☐ RESTRICTION/ELECTION REPLY

☐ SEQUENCE LISTING ☐ WITH DISK


☐ RCE / CPA TRANSMITTAL (circle one)

☐ NOTICE OF APPEAL

☐ APPEAL BRIEF (TRIPPLICATE)

☐ REPLY BRIEF (TRIPPLICATE)

☒ OTHER Response to Notice of Incomplete Reply Nonprovisional



☐ ASSIGNMENT

☐ INFORMATION DISCLOSURE STATEMENT

☐ FORM 1449 & _____ PATENTS/PUBS

☐ PRIORITY DOCUMENT(S) NO. _____

☐ DECLARATION UNDER § _____

☐ LETTER TO DRAFTSMAN

☐ _____ SHEETS OF DRAWINGS

☐ ISSUE FEE TRANSMITTAL FORM

☐ MAINTENANCE FEE LETTER

B&N-2

RECEIVED

JAN 08 2004

OFFICE OF PETITIONS